Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of omalizumab mechanism of action in chronic idiopathic urticaria refractory to H1 antihistamines
2011-004216-31Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing Xolair with Placebo (2 arms). Primary endpoint: Relative change from baseline in FcεRI and/or IgE-positive skin cells at Week 12. Started Dec 2011; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2011-004216-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004216-31.